issues
February 2009
Download PDFTABLE OF CONTENTS
Orally Dissolving Film Strips (ODFS): The Final Evolution of Orally Dissolving Dosage Forms
Madhu Hariharan, PhD, and B. Arlie Bogue, PhD, focus their discussion mainly on films for oral delivery of drug to the GI tract as well as address other prospective manifestations of this dosage form.
Continued Drug Delivery Opportunities in Diabetes Management
Frost & Sullivan Analyst Daniel Ruppar asks the question whether there is still an opportunity for an inhaled diabetes drug.
Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges
Frank Y. Xie, PhD; Qing Zhou, PhD; Ying Liu, MS; Samuel Zalipsky, PhD; and Xiaodong Yang, MD, PhD; provides an overview of the critical steps in the development of siRNA therapeutics, from the selection of siRNA specific for the target of interest to the development of novel formulations for efficient in vivo systemic delivery of siRNA therapeutics.
Speeding Drugs With Non-Traditional Delivery Mechanisms to Market
Robert R. Andrews, MS, MBA, and Russell L. Newton, MS, provide guidance on how to overcome the most commonly encountered issues in developing non-traditionally delivered drugs.
A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility
Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.
Nanoparticles in Cancer Research: A Novel Drug Delivery & Pharmacological Approach
Priyal Patel, Maulik A. Acharya, and Jayvadan Patel, PhD, provide a balanced update of exciting pharmacological and potentially toxicological developments of nanoparticles in cancer research.
Achieving Optimal Particle Size Distribution in Inhalation Therapy
Thomai (Mimi) Panagiotou, PhD, addresses many of the concerns medical device manufacturers and their pharmaceutical partners have when attempting to achieve the correct particle size for an inhalation device.
The Untapped Potential of Carbohydrates in Drug Discovery & Development
Executive Summary: David Platt, CEO of Pro-Pharmaceuticals, says carbohydrate molecules have been shown to play an important role in major diseases, including cancer, cardiovascular disease, Alzheimer’s disease, inflammatory disease, and viral infections.
How Your Central Lab Can Keep Clinical Trials Flexible & Cost Effective
Contributor Cindy H. Dubin poses questions to central lab executives about how improved forecasting methods and alternative foreign locations could result in better data generated during clinical trials.
Drug Delivery Prospects for the Next Decade: An Informal Survey of Big Pharma
Josef Bossart, PhD, conducted an informal survey with Big Pharma personnel to get their sense of how drug delivery fit into their plans now and for the next decade.
DEPARTMENTS
Market News & Trends
Advanced Delivery Devices
A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe
Technology Showcase
COVER
FEATURES
